Dow Inc.
DOW
$28.90
-0.45%
Dow Inc. is one of the world's largest plastics and chemicals producers, operating through three reportable segments — Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings — that supply polyethylene, polypropylene, and a broad range of industrial and consumer chemical products to global end markets. Spun off from the DowDuPont merger in 2019, the company holds a top-five global position in upstream plastics production and is a bellwether for the commodity chemicals cycle, with scale, feedstock flexibility, and an integrated global asset base as its core competitive identity. The current investor narrative is dominated by a severe petrochemical downcycle compounded by geopolitical shock: the closure and subsequent reopening of the Strait of Hormuz triggered a supply-chain disruption that management warned could take roughly 275 days to clear, pressuring volumes and margins while oil-price volatility whipsaws feedstock economics. Against this backdrop, Dow is being debated as a deep-value, dividend-supported cyclical recovery play — bulls point to cost-saving initiatives, optimistic Q2 guidance, and a 114-year dividend streak, while bears focus on widening losses, negative free cash flow, and the risk that the downcycle persists longer than the market expects.…
DOW
Dow Inc.
$28.90
Related headlines
Investment Opinion: Should I buy DOW Today?
We assign a Hold rating on Dow Inc. with a cautious bias. The core thesis is that Dow is a deep-value cyclical play trading at a steep discount to historical multiples, but the timing of a recovery is highly uncertain and the near-term fundamentals continue to deteriorate. The analyst consensus rating of 'buy' (mean 2.47) and average target price of $34.69 imply 19.5% upside, but the wide target range of $29.00 to $42.00 reflects genuine disagreement about the recovery trajectory.
Supporting evidence for the Hold includes: (1) valuation at 0.416x sales and 1.04x book, near multi-year lows; (2) an 8.96% dividend yield backed by a 114-year streak and $4.235 billion in cash; (3) Q1 2026 free cash flow turned positive at $621 million, suggesting the cash burn is moderating; and (4) analyst EPS estimates of $1.94 for the forward period imply a significant recovery from the current loss. However, these positives are offset by a 6.11% YoY revenue decline, a net margin of -6.56%, and negative trailing FCF of $1.395 billion. The forward PE of 16.09x is not cheap for a company with negative earnings and uncertain growth.
The biggest risks that could invalidate the thesis are a dividend cut, a prolonged petrochemical downcycle beyond 2027, and a failure to achieve the cost-saving targets. We would upgrade to Buy if the stock drops below $25 (implying a 0.36x PS ratio) or if gross margins recover above 10% for two consecutive quarters. We would downgrade to Sell if the dividend is cut or if revenue declines accelerate below -10% YoY. Relative to its own history and peers, Dow appears undervalued on a price-to-sales basis, but the market is correctly pricing in a high degree of uncertainty. The stock is fairly valued at current levels, with the risk/reward balanced but skewed toward value investors with a long time horizon.
Sign up to view all
DOW 12-Month Price Forecast
Dow presents a classic deep-value cyclical opportunity with significant risks. The stock is cheap on almost every metric, but the earnings recovery is uncertain and the balance sheet is stretched. The low beta and high dividend yield may attract income investors, but the negative free cash flow and declining revenue are red flags. We would upgrade to bullish if gross margins recover above 10% and revenue stabilizes, or downgrade to bearish if the dividend is cut or if the downcycle extends beyond 2027. The risk/reward is balanced, with the base case (55% probability) suggesting a modest recovery to $30-35.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dow Inc.'s 12-month outlook, with a consensus price target around $34.69 and implied upside of +20.0% versus the current price.
Average Target
$34.69
0 analysts
Implied Upside
+20.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$29 - $42
Analyst target range
Dow is covered by 16 analysts with a consensus recommendation of "buy" (recommendation mean of 2.47 on a scale where 1 is strong buy and 5 is strong sell, indicating a moderate buy leaning toward hold). The average target price is $34.69, which implies approximately 19.5% upside from the current price of $29.03, while the low target of $29.00 is essentially at the current price (0% downside) and the high target of $42.00 implies 44.7% upside. The consensus leans cautiously bullish — the average target suggests meaningful upside, but the recommendation mean of 2.47 is closer to hold than strong buy, and the fact that the low target equals the current price indicates that even the most bearish analyst sees limited further downside, which could be interpreted as a valuation floor. The target range of $29.00 to $42.00 represents a spread of $13.00, or 44.8% of the average target, which signals moderate-to-high uncertainty about the recovery trajectory — a tight spread would indicate strong conviction, while this wide range reflects genuine disagreement about the timing and magnitude of the cyclical turn. The high target of $42.00, near the 52-week high, assumes a full cyclical recovery with margin expansion back toward mid-cycle levels, likely driven by petrochemical spread normalization, successful cost-saving initiatives, and resolution of Middle East supply-chain disruptions; the low target of $29.00 prices in a prolonged downcycle with continued margin compression and potential dividend concerns. Institutional ratings show a mixed but slightly deteriorating pattern: recent actions include RBC Capital downgrading from Outperform to Sector Perform on July 1, 2026, while Argus Research upgraded from Hold to Buy on May 13, 2026, and Citigroup maintained Buy ratings in May and June 2026. B of A Securities maintained an Underperform rating on June 30, 2026, and BMO Capital maintained Market Perform on July 6, 2026, indicating that the bearish camp remains vocal. The estimated EPS average of $1.94 for the forward period, with a range of $1.55 to $2.20, implies a significant recovery from the current trailing loss, and the estimated revenue average of $44.33 billion (range $42.24 billion to $47.78 billion) suggests analysts expect roughly flat to modestly higher revenue versus the current run-rate — meaning the earnings recovery is expected to come primarily from margin expansion rather than top-line growth, which is a critical assumption to monitor.
Drowning in data?
Find the real signal!
Bulls vs Bears: DOW Investment Factors
The bear case currently has stronger evidence, as Dow's fundamental deterioration is quantifiable and ongoing: revenue is declining, margins are at cycle troughs, and free cash flow is negative. However, the bull case rests on valuation and mean reversion—at 0.42x sales and 1.04x book, the stock already discounts a severe downturn, and the 8.96% dividend yield plus analyst targets imply significant upside if the cycle turns. The single most important tension is whether the petrochemical downcycle inflects within the next 12 months; if it does, the stock could re-rate toward $42, but if it persists, the dividend and balance sheet come under pressure. The low beta and high short interest add a tactical element, but the structural underperformance versus the market suggests investors are not yet convinced of a recovery.
Bullish
- Deep value at 0.42x sales: Dow trades at a price-to-sales ratio of just 0.416x, a roughly 75-85% discount to its own 2021-2022 upcycle range of 2.2x-3.8x. The stock also trades essentially at book value (P/B of 1.04x), near the bottom of its historical 0.93x-3.04x band, suggesting the market is pricing in a worst-case scenario.
- Analyst consensus sees 19.5% upside: The average analyst target price of $34.69 implies 19.5% upside from the current $29.03, with a high target of $42.00 (44.7% upside) and a low target of $29.00 that sits exactly at the current price. The fact that even the most bearish analyst sees no downside provides a valuation floor argument.
- Dividend yield of 8.96% with 114-year streak: Dow offers an extraordinarily high dividend yield of 8.96%, roughly 6-7x the S&P 500 average, backed by a 114-year dividend streak and $4.235 billion in cash. The Q1 2026 dividend payment of $252 million was covered by $1.124 billion in operating cash flow, and management has continued the $0.35 quarterly payout.
- Cash burn moderating, cost cuts underway: Q1 2026 free cash flow turned positive at $621 million versus -$594 million in Q1 2025, and capital expenditure was cut to $503 million from $685 million year-over-year. Management's cost-saving initiatives and optimistic Q2 guidance suggest the trough may be near.
Bearish
- Revenue declining 6.1% YoY: Q1 2026 revenue of $9.794 billion fell 6.11% year-over-year from $10.431 billion, extending a multi-quarter contraction. The sequential trend also weakened from $10.104 billion in Q2 2025 to $9.460 billion in Q4 2025, with only a modest uptick in Q1 2026 that still left the top line below year-ago levels.
- Deeply unprofitable with negative FCF: Q1 2026 net income was -$445 million (EPS of -$0.74), with a net margin of -6.56% and an operating margin of just 0.65%. Trailing free cash flow is -$1.395 billion, and the payout ratio of -56.8% means the dividend is not covered by trailing earnings.
- Gross margin collapsed to 6.53%: Gross margin has compressed from 11.38% in Q2 2024 to 6.53% in Q1 2026, a 485 basis point decline, reflecting the severe petrochemical margin squeeze. EBITDA of just $195 million in Q1 2026 (1.99% margin) versus $1.481 billion in Q2 2024 highlights how far profitability has fallen.
- Elevated debt and negative ROE: The debt-to-equity ratio of 1.224 is elevated for a cyclical chemical company, and ROE is deeply negative at -16.39%. With $4.235 billion in cash but negative trailing FCF, a prolonged downcycle could force a difficult choice between maintaining the dividend and preserving liquidity.
DOW Technical Analysis
Dow is in a sustained downtrend that has partially reversed into a volatile recovery attempt, with the stock at $29.03 after a 1-year gain of 16.03% but a 6-month decline of 20.73%. The current price sits at roughly 39.8% of its 52-week range (low of $20.65, high of $42.74), meaning it has recovered meaningfully off the lows but remains far below the highs — a positioning that reflects a market still skeptical of a durable cyclical turn rather than a momentum breakout. The 1-year positive return against a deeply negative 6-month return signals that the bulk of the gains came early in the period and have since been substantially eroded, leaving the stock in a fragile, range-bound posture. Recent momentum is clearly negative and decelerating: the 1-month change of -5.04% and 3-month change of -14.24% show accelerating near-term weakness, and the 1-month relative strength versus SPY of -3.98% confirms Dow is underperforming a market that itself fell only 1.06% over the same period. The 3-month relative strength of -17.28% and 6-month relative strength of -36.13% reveal a persistent and widening divergence from the broader market, suggesting this is not a temporary pullback but a structural underperformance trend. Notably, the 1-year relative strength of -0.19% is essentially flat versus SPY's +16.22%, meaning Dow has matched the market over 12 months only by front-loading gains that have since reversed — a classic pattern of a value trap or a bottoming process, depending on whether the downcycle inflects. Key technical levels are well-defined: support rests at the 52-week low of $20.65, roughly 28.8% below the current price, while resistance sits at the 52-week high of $42.74, about 47.2% above. A breakout above $42.74 would signal a genuine cyclical recovery and likely require a fundamental catalyst such as a petrochemical margin inflection or a Hormuz-driven supply normalization, whereas a breakdown below $20.65 would confirm the bear thesis and could trigger further capitulation. The beta of 0.424 is unusually low for a commodity chemical stock, indicating Dow has been roughly 58% less volatile than the market — a defensive characteristic that may reflect its dividend support and deep-value positioning, but which also means the stock may lag in a sharp risk-on rally and offers limited upside torque for momentum traders. The maximum drawdown of -35.47% over the period underscores that despite the low beta, the stock has experienced severe peak-to-trough pain, and the short ratio of 4.43 suggests a meaningful short interest overhang that could fuel a squeeze on any positive catalyst.
Beta
0.42
0.42x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$21-$43
Price range past year
Annual Return
+15.4%
Cumulative gain past year
| Period | DOW Return | S&P 500 |
|---|---|---|
| 1m | -7.0% | -2.0% |
| 3m | -12.3% | +1.4% |
| 6m | -23.3% | +15.0% |
| 1y | +15.4% | +15.7% |
| ytd | +19.1% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOW Fundamental Analysis
Dow's revenue trajectory is deteriorating: Q1 2026 revenue of $9.794 billion declined 6.11% year-over-year from $10.431 billion in Q1 2025, extending a multi-quarter pattern of contraction. The sequential trend is also weak — revenue fell from $10.104 billion in Q2 2025 to $9.973 billion in Q3 2025, then to $9.460 billion in Q4 2025, before a modest sequential uptick to $9.794 billion in Q1 2026 that still left the top line below year-ago levels. Segment data shows Packaging & Specialty Plastics as the largest contributor at $4.919 billion, followed by Industrial Intermediates & Infrastructure at $2.626 billion and Performance Materials & Coatings at $2.080 billion, with the plastics segment's exposure to commodity polyethylene pricing making it the primary swing factor for overall growth. The persistent revenue decline reflects both volume weakness from Middle East supply-chain disruptions and price deflation in commodity chemicals, and until polyethylene and polypropylene spreads stabilize, the top line is unlikely to inflect meaningfully. Profitability has collapsed: Q1 2026 net income was -$445 million (EPS of -$0.74), a sharp deterioration from -$307 million in Q1 2025, and the gross margin of just 6.53% is extraordinarily thin for a chemical producer — well below the 8.43% gross margin in Q4 2024 and the 11.38% in Q2 2024. The operating margin of 0.65% and net margin of -6.56% confirm that Dow is barely covering its cost of goods and is deeply unprofitable on a net basis, with Q4 2025's -$1.543 billion net loss (a -16.31% net margin) representing the cycle's trough. The gross margin compression from 11.38% in mid-2024 to 6.53% in Q1 2026 — a 485 basis point decline — illustrates the severity of the petrochemical margin squeeze, and the EBITDA of just $195 million in Q1 2026 (a 1.99% EBITDA margin) versus $1.481 billion in Q2 2024 highlights how far profitability has fallen. Balance sheet and cash flow metrics present a mixed but concerning picture: the debt-to-equity ratio of 1.224 is elevated, ROE is deeply negative at -16.39%, and trailing free cash flow is -$1.395 billion, meaning the company is burning cash. However, the current ratio of 1.967 indicates adequate short-term liquidity, and Q1 2026 free cash flow was actually positive at $621 million (versus -$594 million in Q1 2025), suggesting the cash burn may be moderating. The company paid $252 million in dividends in Q1 2026 against $1.124 billion in operating cash flow, and with $4.235 billion in cash on the balance sheet, the dividend appears covered for now — but the payout ratio of -56.8% and the negative trailing FCF mean that a prolonged downcycle would force a difficult choice between maintaining the dividend and preserving liquidity. The capital expenditure of $503 million in Q1 2026 was well below the $685 million in Q1 2025, indicating management is already pulling back on growth spending to conserve cash.
Quarterly Revenue
$9.8B
2026-03
Revenue YoY Growth
-6.1%
YoY Comparison
Gross Margin
6.5%
Latest Quarter
Free Cash Flow
$-1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOW Overvalued?
Because Dow's trailing net income is negative (EPS of -$0.158, net margin of -6.56%), the trailing PE ratio of -6.34x is not meaningful, and the appropriate primary metric is the price-to-sales ratio, which stands at 0.416x — an extremely low absolute level that reflects the market's deep pessimism about the company's earnings power. The forward PE of 16.09x, based on estimated EPS of $1.94, is the more informative metric: it implies the market expects a substantial earnings recovery from the current loss, and the gap between the meaningless trailing PE and the 16.09x forward PE encapsulates the entire bull-bear debate — the market is pricing in a cyclical rebound that has not yet materialized. The EV/Sales of 0.923x and EV/EBITDA of 27.29x further illustrate the distortion: the EV/EBITDA multiple is elevated precisely because EBITDA has collapsed to near-zero, and it would normalize rapidly if margins recover. On a price-to-book basis, Dow trades at 1.039x, essentially at book value, which for a capital-intensive chemical company with $4.235 billion in cash and substantial PP&E provides a valuation floor argument. Peer comparison is challenging given the absence of explicit industry average multiples in the provided data, but contextually, Dow's 0.416x PS ratio and 1.04x PB ratio are at the low end of what large-cap chemical producers typically command — historically, Dow traded at PS ratios of 2.2x to 3.8x during the 2021-2022 upcycle, and even in the 2023-2024 downcycle it ranged from 1.6x to 3.5x. The current 0.416x PS represents a roughly 75-85% discount to its own recent historical range, a compression that reflects both the severity of the earnings downturn and the market's skepticism about recovery timing. The dividend yield of 8.96% is extraordinarily high for a large-cap industrial — roughly 6-7x the S&P 500 average — and while it signals deep value, it also raises the risk of a dividend cut if cash flow does not recover, which is the key tail risk embedded in the valuation. Historically, Dow's PE ratio ranged from 5.6x to 21.2x during profitable quarters in 2021-2024, and its PB ratio ranged from 0.93x to 3.04x; the current 1.04x PB is near the bottom of that band, suggesting the market is pricing in a worst-case scenario. The PEG ratio of 0.019 is distorted by the negative earnings base and should be disregarded, but the price-to-free-cash-flow ratio of 16.12x (using the positive Q1 2026 FCF annualized) suggests that if cash generation normalizes, the stock is not expensive on a cash flow basis.
PE
-6.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.3x
Enterprise Value Multiple
Investment Risk Disclosure
Dow faces significant financial and operational risks. The company reported a Q1 2026 net loss of $445 million and negative trailing free cash flow of $1.395 billion, with a gross margin of just 6.53%—down from 11.38% in mid-2024. The debt-to-equity ratio of 1.224 is elevated, and with a payout ratio of -56.8%, the 8.96% dividend yield may be unsustainable if cash flow does not recover. Revenue concentration in Packaging & Specialty Plastics ($4.919 billion in Q1 2026) ties the company's fortunes to commodity polyethylene pricing, which remains volatile due to Middle East supply disruptions. The 275-day timeline to clear the Strait of Hormuz supply shock, as warned by management, suggests operational headwinds will persist well into 2027.
Market and competitive risks are equally pressing. Dow trades at a forward PE of 16.09x, which already prices in a significant earnings recovery from the current loss; if that recovery fails to materialize, multiple compression could drive the stock lower. The beta of 0.424 indicates low market correlation, but the stock has still suffered a max drawdown of -35.47%, and its 6-month relative strength versus SPY is -36.13%, reflecting a structural underperformance trend. Competitive pressures from lower-cost Middle Eastern and Asian producers could permanently impair Dow's margin structure, and regulatory headwinds around plastics and emissions add long-term uncertainty. Recent analyst actions are mixed, with RBC Capital downgrading to Sector Perform in July 2026 and B of A maintaining Underperform, signaling that the bearish camp remains vocal.
The worst-case scenario involves a prolonged downcycle where petrochemical spreads fail to recover, forcing Dow to cut its dividend and potentially dilute equity to shore up liquidity. In this scenario, the stock could retest its 52-week low of $20.65, representing a 28.8% decline from the current price of $29.03. If the low analyst target of $29.00 is breached and sentiment deteriorates further, a drop toward the 2020 lows (around $20) is plausible, implying a total downside of approximately 29-31%. This would be triggered by a combination of continued revenue declines, a dividend cut, and a broader market rotation away from cyclical value stocks.
FAQ
The key risks include: 1) Dividend risk—the payout ratio is -56.8%, and a cut could trigger a sharp sell-off; 2) Cyclical risk—revenue is declining 6.1% YoY and margins are at cycle troughs, with no clear inflection; 3) Balance sheet risk—debt-to-equity of 1.224 is elevated, and negative free cash flow of -$1.395 billion limits financial flexibility; 4) Macro risk—the Strait of Hormuz supply disruption could take 275 days to clear, and a global recession would further pressure demand. These risks are ranked from most to least severe, with the dividend being the most immediate concern.
Our 12-month forecast has three scenarios: bull case (25% probability) targets $38-42, assuming a cyclical recovery and margin expansion; base case (55% probability) targets $30-35, assuming a slow recovery with EPS around $1.94; and bear case (20% probability) targets $20-25, assuming a prolonged downcycle and dividend cut. The base case is most likely, supported by analyst average target of $34.69 and estimated EPS of $1.94. The key assumption is that petrochemical spreads normalize gradually without a global recession. If the recovery is faster, the stock could hit $42; if it stalls, $20 is possible.
DOW appears undervalued on a price-to-sales and price-to-book basis, trading at 0.416x sales and 1.04x book, which is near the bottom of its historical range. During the 2021-2022 upcycle, the stock traded at 2.2x-3.8x sales, implying a 75-85% discount today. However, the forward PE of 16.09x is not cheap for a company with negative earnings, as it prices in a significant recovery. The market is valuing Dow as if the downcycle will persist, but if earnings recover to $1.94 per share, the stock could re-rate higher. Relative to peers, Dow's valuation is at the low end, but the high debt and negative ROE justify a discount.
DOW is a high-risk, high-reward deep-value play that may be suitable for income-focused investors willing to tolerate volatility. The stock offers an 8.96% dividend yield and trades at just 0.42x sales, but it is currently unprofitable with a net margin of -6.56% and negative free cash flow of -$1.395 billion. Analyst consensus target of $34.69 implies 19.5% upside, but the low target of $29.00 suggests limited downside from current levels. The biggest risk is a dividend cut if cash flow does not recover. For long-term investors with a 3-5 year horizon, the risk/reward is favorable, but short-term traders should be cautious given the 6-month relative strength of -36.13% versus the market.
DOW is more suitable for long-term investment (3-5 years) due to its cyclical nature and deep-value characteristics. The stock has a low beta of 0.424, which reduces volatility, but it has still experienced a max drawdown of -35.47%. The 8.96% dividend yield provides income while waiting for a recovery, but the negative payout ratio means the dividend is at risk. Short-term trading is not recommended given the structural underperformance versus the market (6-month relative strength of -36.13%). A minimum holding period of 2-3 years is suggested to allow the petrochemical cycle to turn. Investors should monitor quarterly earnings and dividend announcements closely.